Current situation and challenges of polyhydroxyalkanoates-derived nanocarriers for cancer therapy

Q1 Engineering Smart Materials in Medicine Pub Date : 2024-10-30 DOI:10.1016/j.smaim.2024.10.004

Xiao-Yun Huang , Zheng-Dong Qi , Jin-Wei Dao , Dai-Xu Wei

{"title":"Current situation and challenges of polyhydroxyalkanoates-derived nanocarriers for cancer therapy","authors":"Xiao-Yun Huang , Zheng-Dong Qi , Jin-Wei Dao , Dai-Xu Wei","doi":"10.1016/j.smaim.2024.10.004","DOIUrl":null,"url":null,"abstract":"<div><div>The sustained-release system for chemotherapeutic drugs or photosensitizer based on drug-loaded biopolyester nanocarriers can effectively reduce the overall dosage and frequency of administration, thereby mitigating side effects such as immunosuppression and drug resistance caused by prolonged chemotherapy. Compared to polylactic acid (PLA), microorganism-derived polyhydroxyalkanoates (PHAs) exhibits superior biocompatibility and more flexible drug release behavior due to their diverse monomer compositions, slower degradation behavior, and milder acidic degradation products, 3-hydroxybutyric acid (3HB). It explains PHAs are more suitable carriers for chemotherapeutic drugs. In this review, we summarize the current situation of PHA-derived nanocarriers (PHA-NCs) for cancer therapy, including the advantages, preparation methods, and anticancer applications. Furthermore, we also analyzed the current limitations in the application of PHA-NCs for cancer therapy and proposed existing challenges along with strategies for future development. With the rapid advancements in synthetic biology and nanomedicine, we believe that PHA will once again attract significant attention.</div></div>","PeriodicalId":22019,"journal":{"name":"Smart Materials in Medicine","volume":"5 4","pages":"Pages 529-541"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Smart Materials in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S259018342400053X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Engineering","Score":null,"Total":0}

引用次数: 0

Abstract

The sustained-release system for chemotherapeutic drugs or photosensitizer based on drug-loaded biopolyester nanocarriers can effectively reduce the overall dosage and frequency of administration, thereby mitigating side effects such as immunosuppression and drug resistance caused by prolonged chemotherapy. Compared to polylactic acid (PLA), microorganism-derived polyhydroxyalkanoates (PHAs) exhibits superior biocompatibility and more flexible drug release behavior due to their diverse monomer compositions, slower degradation behavior, and milder acidic degradation products, 3-hydroxybutyric acid (3HB). It explains PHAs are more suitable carriers for chemotherapeutic drugs. In this review, we summarize the current situation of PHA-derived nanocarriers (PHA-NCs) for cancer therapy, including the advantages, preparation methods, and anticancer applications. Furthermore, we also analyzed the current limitations in the application of PHA-NCs for cancer therapy and proposed existing challenges along with strategies for future development. With the rapid advancements in synthetic biology and nanomedicine, we believe that PHA will once again attract significant attention.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

用于癌症治疗的聚羟基烷酸酯纳米载体的现状与挑战

基于载药生物聚酯纳米载体的化疗药物或光敏剂缓释系统可有效减少总体剂量和给药频率，从而减轻长期化疗引起的免疫抑制和耐药性等副作用。与聚乳酸（PLA）相比，微生物衍生的聚羟基烷酸酯（PHA）因其单体成分多样、降解行为缓慢、降解产物 3-hydroxybutyric acid（3HB）酸性较弱等特点，具有更优越的生物相容性和更灵活的药物释放行为。这说明 PHAs 更适合作为化疗药物的载体。在这篇综述中，我们总结了PHA衍生纳米载体（PHA-NCs）用于癌症治疗的现状，包括其优势、制备方法和抗癌应用。此外，我们还分析了目前 PHA-NCs 在癌症治疗中应用的局限性，并提出了现有挑战和未来发展策略。随着合成生物学和纳米医学的快速发展，我们相信 PHA 将再次引起人们的广泛关注。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊